Best Diabetes Companies in South Korea
The 31 best Diabetes companies in South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Polus.
- Insulin Pumps Market Growth 2022-2028: The Growing Prevalence of Diabe
Ranked: Best Diabetes companies in South Korea
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Polus Korean, Early-stage Biopharma company developing biosimilars to existing therapeutics | $6M | 119 mo ago | Deadpooled | S H Nam CEO | 2015 | — | 20 patents Recombinant insulin production and purification, including expression tags and precursor conversion | — |
| 2 | GlucoFit AI-powered blood sugar management solution | $901K | 32 mo ago | Seed | Yang Hyeok-Yong CEO | 2022 | TypeScriptGraphQLNode.js+17 | — | — |
| 3 | Orange Biomed Healthcare startup that integrates lab-level technology devices for diabetic patient | — | 23 mo ago | Series A | — | 2021 | WordPressMySQLPHP+22 | 34 patents Blood cell analysis devices for glycated hemoglobin (HbA1c) measurement | — |
| 4 | PINOTBIO Provider of therapeutics solution for cancer, glaucoma and other diseases | — | 42 mo ago | Seed | Hyun Cho Co-Founder & COO | 2017 | — | 118 patents Oncology therapeutics: antibody‑drug conjugates and novel cytotoxic small‑molecule derivatives. | — |
| 5 | SD Biosensor Provider of point-of-care diagnostics for multiple diseases | — | 76 mo ago | Public | Hyo Lee Co-CEO | 2001 | PHPBootstrapAmazon ALB+9 | 174 patents Point‑of‑care biosensor devices for continuous glucose monitoring and rapid nucleic‑acid testing | — |
| 6 | EoFlow Developer of a wearable disposable insulin patch for diabetes patients | — | 112 mo ago | Acquired | Jesse Kim CEO | 2011 | CKEditorPHPBootstrap+13 | 418 patents Advanced insulin and drug delivery devices with smart dosing algorithms and electroosmotic pumps | — |
| 7 | AULBIO Provider of microsphere based drug delivery system | — | — | Funding Raised | Taekun An CEO | 2018 | — | 28 patents Controlled-release microsphere drug delivery for GLP‑1 peptides, cariprazine, and varenicline | — |
| 8 | Axceso Biopharma Provider of therapeutics for treating multiple diseases | — | — | Funding Raised | — | 2010 | — | 44 patents Patents concentrated in chemistry & materials | — |
Top 6 Diabetes companies in South Korea
#1
Seed · Seoul, Seoul · founded 2022$900.7Kraised▾
AI-powered blood sugar management solution. It uses a Continuous Glucose Monitoring sensor attached to the arm and linked to the Glucofit app, allowing users to measure blood sugar data in real-time.
- Feb 2024Seed$900.7K
#2
Deadpooled · Seoul, Seoul · founded 2015$6Mraised▾
Polus Global is a very early-stage Korean biopharmaceutical company developing Biosimilars for existing therapeutics. In their pipeline currently, they are developing biosimilars for: Insulin Glargine (PDP808 , Biosimilar to Lantus from Sanofi for Diabetes), Somatropin (PDP 805, Biosimilar to Norditropin from Novo Nordisk for Growth Hormone Deficiency), Ranibizumab (PDP 807, Macular degeneration), Insulin Lispro (PDP 815, Biosimilar to Humalog from Lilly for Diabetes). As of Dec.2016, the company had announced that it will partner with Parexel (global CRO) for its clinical trials on the biosimilars.
- Dec 2016Series A$5.9M
#3
Series A · Seoul, Seoul · founded 2021 · 8 employees—raised▾
Orange Biomed is a healthcare startup that offers accessible lab-level technology for diabetes care. Their OBM rapid A1c test produces highly accurate results and requires only a single drop of blood to produce. They are currently conducting studies of OBM rapid A1c, the world's first glycated hemoglobin analyzer through single-cell analysis.
#4
Seed · Suwon-si, Gyeonggi-do · founded 2017 · 9 employees—raised▾
Provider of therapeutics solution for cancer, glaucoma, and other diseases. The company flagship product NXT-301, prevent the hyper-methylation in mature cells, and NXT-101 target the IOP (intraocular pressure), cGMP (cyclic glucoside monophosphate), and sGC (soluble guanylate cyclase) for treating diabetes.
- Apr 2023Seed—
#5
Public · Suwon-si, Gyeonggi-do · founded 2001 · 175 employees—raised▾
Provider of point-of-care diagnostics for multiple diseases. It offers technology for POC molecular diagnostics, fluorescent immunoassay, immunochromatography, BGMS and CGMS. The products include SD A1care is an immunochromatographic analyzer for HbA1c levels in blood, SD Lipidocare for monitoring blood cholesterol levels, and SD GlucoNavii is for rapid glucose measurement.
- 2020Post IPO—
#6
Acquired · Seongnam-si, Gyeonggi-do · founded 2011 · 150 employees—raised▾
Developer of a wearable disposable insulin patch for diabetes patients. The patch is entirely tubeless and can be worn on any part of the body. The patch uses a stainless steel needle to deliver the drug. The patch can be controlled by a handheld touch-screen controller unit. It also extracts data from the patch to provide the user with the convenience of managing and analyzing the data.
- 2017Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diabetes coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.